Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Renal cell carcinomas (RCC) commonly retain wild-type but functionally inactive p53, which is repressed by an unknown dominant mechanism. To help reveal this mechanism, we screened a diverse chemical library for small molecules capable of restoring p53-dependent transactivation in RCC cells carrying a p53-responsive reporter. Among the compounds isolated were derivatives of 9-aminoacridine (9AA), including the antimalaria drug quinacrine, which strongly induced p53 function in RCC and other types of cancer cells. Induction of p53 by these compounds does not involve genotoxic stress and is mediated by suppression of NF-kappaB activity. In contrast to agents that target IkappaB kinase 2, 9AA and quinacrine can effectively suppress both basal and inducible activities of NF-kappaB, representing inhibitors of a previously undescribed type that convert NF-kappaB from a transactivator into a transrepressor, leading to accumulation of inactive nuclear complexes with unphosphorylated Ser-536 in the p65/RelA subunit. p53 function in RCC can be restored by ectopic expression of a superrepressor of IkappaB as effectively as by 9AA-derived compounds. These findings suggest that the complete or partial repression of p53 observed in many tumors can be the result of constitutive activation of NF-kappaB. The results demonstrate, in principle, the possibility to kill cancer cells selectively through simultaneous inhibition of NF-kappaB and activation of p53 by a single small molecule and suggest anticancer applications for the well known antimalaria drug quinacrine.

[1]  L. Zwelling,et al.  Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. , 1989, The Journal of biological chemistry.

[2]  Masafumi Ohtsubo,et al.  Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells , 2001, Oncogene.

[3]  S. Kern,et al.  High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter , 2002 .

[4]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[5]  N. Perkins,et al.  Transcriptional Cross Talk between NF-κB and p53 , 1999, Molecular and Cellular Biology.

[6]  M. Merville,et al.  Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation , 2005 .

[7]  Toby Lawrence,et al.  IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation , 2005, Nature.

[8]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[9]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[10]  Douglas B. Evans,et al.  Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis , 2003, Oncogene.

[11]  K. Vousden,et al.  Loss of Nuclear Factor-κB Is Tumor Promoting but Does Not Substitute for Loss of p53 , 2004, Cancer Research.

[12]  S. Verstovsek,et al.  Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies , 2004, Cancer.

[13]  Elliott Kieff,et al.  Role of NF-κB in Cell Survival and Transcription of Latent Membrane Protein 1-Expressing or Epstein-Barr Virus Latency III-Infected Cells , 2004, Journal of Virology.

[14]  D. Wallace.  The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. , 1989, Seminars in arthritis and rheumatism.

[15]  S. Ghosh,et al.  The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1 , 2002 .

[16]  H. Kalthoff,et al.  Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer , 2003, International journal of cancer.

[17]  Masafumi Ohtsubo,et al.  Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. , 2003, Carcinogenesis.

[18]  I. Han,et al.  Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. , 2003, Cellular signalling.

[19]  R. Gaynor,et al.  Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression , 2003, Nature.

[20]  L. Baldi,et al.  Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IB- (*) , 1996, The Journal of Biological Chemistry.

[21]  J. Brady,et al.  Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. , 2005, Frontiers in bioscience : a journal and virtual library.

[22]  A. Ullrich,et al.  Dominant Negative Form of Signal-regulatory Protein-α (SIRPα/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-κB* , 2002, The Journal of Biological Chemistry.

[23]  P. Chumakov,et al.  p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism , 2004, Cancer Research.

[24]  G. W. Peet,et al.  IKKα, IKKβ, and NEMO/IKKγ Are Each Required for the NF-κB-mediated Inflammatory Response Program* , 2002, The Journal of Biological Chemistry.

[25]  R. Orlowski,et al.  NF-?B as a therapeutic target in cancer , 2002 .

[26]  M. Tariq,et al.  Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers. , 1997, Digestion.